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Application of the Ugi reaction with multiple
amino acid-derived components: synthesis and
conformational evaluation of piperazine-based
minimalist peptidomimetics†
Mattia Stucchi,a Silvia Cairati,a Rengul Cetin-Atalay,b Michael S. Christodoulou,a
Giovanni Grazioso,c Gennaro Pescitelli,d Alessandra Silvani,*a Deniz Cansen Yildirime
and Giordano Lesmaa
The concurrent employment of α-amino acid-derived chiral components such as aldehydes and α-iso-
cyanoacetates, in a sequential Ugi reaction/cyclization two-step strategy, opens the door to the synthesis
of three structurally distinct piperazine-based scaﬀolds, characterized by the presence of L-Ala and/or
L-Phe-derived side chains and bearing appropriate functionalities to be easily applied in peptide chemistry.
By means of computational studies, these scaﬀolds have been demonstrated to act as minimalist peptido-
mimetics, able to mimic a well deﬁned range of peptide secondary structures and therefore potentially
useful for the synthesis of small-molecule PPI modulators. Preliminary biological evaluation of two
diﬀerent resistant hepatocellular carcinoma cellular lines, for which diﬀerentiation versus resistance ability
seem to be strongly correlated with well deﬁned types of PPIs, has revealed a promising antiproliferative
activity for selected compounds.
Introduction
Many proteins exert their biological roles as components of
complexes, and their functions are often determined by
specific protein–protein interactions (PPIs). In the past decade,
PPIs have begun to gain attention as viable targets for thera-
peutic intervention, despite the fact that they do not involve
endogenous small molecule ligands that could provide leads
for discovery programmes. In particular, the targeting of
protein–protein interactions relevant to cancer is of fundamen-
tal importance, as the tumor-promoting function of several
aberrantly expressed proteins in the cancerous state is directly
correlated to their ability to interact with a protein-binding
partner.1
A minor fraction of the protein–protein interface residues
can account for the majority of the free energy of binding
between proteins. Statistical analyses of structurally character-
ized protein–protein interfaces have shown that side-chain
substituents account for about 80% of the interactions, with
the polyamide backbone accounting for much less.2 Since it is
well known that the majority of PPIs are mediated by three
main recognition motifs (α-helix, β-turn, or β-strand), an attrac-
tive approach for the discovery of PPI modulators is to mimic
the key interaction residues using small molecule mimetics of
these recognition motifs.3,4
In recent years, an important development in peptide
mimicry has been the emergence of analogues of peptide
secondary structures that mainly present selected side-chains,
with the main-chain polyamide backbone abbreviated or
totally absent. This approach is appealing because small mole-
cules without polyamide backbones are more likely to be orally
bioavailable and proteolytically stable. Compounds that
present only selected side-chains to resemble peptide second-
ary structures were referred to, for the first time, as minimalist
mimics by Burgess and coworkers in 2011.5
Minimalist peptidomimetics are likely to be most useful for
targets where exact binding conformations are unknown. In
these situations such compounds can have the intrinsic ability
to adjust conformations via rotation around a few significant
degrees of freedom, allowing such mimics to easily adapt.
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Minimalist mimics must be amenable to synthetic diversifica-
tion and conveniently accessible with side-chains that corres-
pond to the protein amino acids in order to be generally
useful. In this context, reactions that transform protein
amino acids into carbocyclic or heterocyclic backbones that
have only a few significant degrees of freedom are particularly
useful.
Following our interest in the multicomponent reaction
(MCR)/cyclization approach to the synthesis of conformation-
ally constrained peptidomimetics,6 in this work we demon-
strate for the first time the application of this kind of strategy
to the synthesis of minimalist peptidomimetics.
The atom economy of MCRs,7 their convergent character,
operational simplicity, and the structural diversity and com-
plexity of the resulting molecules make this chemistry excep-
tionally useful for drug discovery processes. In particular, Ugi-
MCRs have undergone developments over the years, and
various modifications in classic isocyanide-based multicompo-
nent reactions (IMCRs) have been achieved by the introduction
of unusual building blocks,8 by transformation of the IMCR
products using post-condensation reactions9,10 or by perform-
ing intramolecular IMCRs with bifunctional inputs.11–13
With regard to the synthesis of peptidomimetics,14 replace-
ment of the amine or acid component in the Ugi reaction with
natural amino acids has had a number of successful out-
comes.15,16 However, only a few reports make use of amino
acid-derived chiral isocyanides in IMCR, probably because of
the believed, but surmountable, configurationally instability of
chiral α-substituted isocyanoacetates.17 Moreover, the use of
amino acid-derived chiral aldehydes as the carbonyl com-
ponent has almost not been documented at all,18 despite its
potential for enabling secondary reactions in order to con-
strain or improve ‘drug-likeness’ of the initial flexible peptide-
like products.
By employing amino acid-derived chiral α-isocyanoacetates
and aldehydes, we pursued the synthesis of minimalist pepti-
domimetics relying on three diﬀerent piperazine-based cores,
spanning side-chains corresponding to two chemically diverse
amino acids, namely L-Ala and L-Phe. Piperazines and their
keto analogs are considered privileged scaﬀolds in medicinal
chemistry, thanks to their versatile binding properties and fre-
quent recurrence among positive hits encountered in biologi-
cal screens.
We also accomplished a computational evaluation of their
secondary structure mimicking properties and a biological
screening within the COST Action CM 1106, entitled Chemical
Approaches to Targeting Drug Resistance in Cancer Stem Cells.19
Results and discussion
As the carbonyl moiety for the Ugi reaction, we focused our
attention on enantiomerically pure N-methyl-N-Boc amino
aldehydes 1 and 2 (Scheme 1), easily prepared in good yields
starting from the corresponding commercial N-Boc amino
acids. Among the reported synthetic procedures for the
preparation of isocyanides from α-amino acid ester hydro-
chlorides, we selected a two-step sequence, involving formyl-
ation of the precursor by reaction with trimethyl orthoformate
without the use of a solvent, followed by dehydration of the
obtained α-N-formylamino acid esters, by means of triphos-
gene as a mild dehydrating agent and N-methyl morpholine as
a base.20 In this way, enantiomerically pure isocyanide com-
ponents 3 and 4 have been prepared. The carboxylic acid and
the amine Ugi components were properly chosen as bifunc-
tional substrates in order to mediate highly selective outcomes
in the post-Ugi cyclization steps.
First of all, using chloroacetic acid and p-anisidine, we
could access a small family of 2,5-diketopiperazine-based
peptidomimetics, as reported in Scheme 1. The Ugi reaction was
conducted after a precondensation time of two hours between
p-anisidine and the amino aldehyde (1 or 2), as suggested by
Carney and coworkers21 in order to avoid the risk of loss of
optical purity of the isocyanoacetates. Ugi compounds 5–8
were all obtained in good yields (87–91%), but as unseparable
diastereoisomeric mixtures, with the exception of compounds
5, which could be separated by flash chromatography (d.r.
5a : 5b 21 : 79). The two Ugi diastereoisomers 5a and 5b were
separately cyclized by means of cesium carbonate in dry aceto-
nitrile,22 to aﬀord 2,5-diketopiperazines 9a and 9b, whose
overall stereochemistry has been assigned on the basis of com-
putational, NMR and CD studies (vide infra). Cyclization per-
formed better for compound 5b, aﬀording 9b in 76% yield,
whereas it proved to be quite diﬃcult for 5a, so that compound
9a could be isolated only in 16% yield, under heating. Evi-
dently, steric factors play a key role in the more or less smooth
achievement of a crowded trisubstituted 2,5-diketopiperazine
ring. The same cyclization reaction was then applied to Ugi
adducts 6–8 to aﬀord the corresponding compounds 10–12,
which proved to be isolable as unique diastereoisomers in
moderate yields (46–56%). This result can be rationalized in
the light of the observed extremely diﬀerent propensity of sep-
arated Ugi diastereoisomers 5 to cyclize to 9.
Starting again from aldehydes 1 and 2 and isocyanoacetates
3 and 4 and varying the acid and amine components in the
Ugi reaction, we could also access strictly related 2,6-diketo-
piperazine-based peptidomimetics 17–20, as reported in
Scheme 2.
In this case the Ugi reaction was performed employing
acetic acid and glycine benzylester as the acid and amine com-
ponent respectively, aﬀording intermediates 13–16, with yields
up to 89% and d.e. up to 84% (from 1H NMR). Catalytic
removal of the benzylester group, followed by activation with
carbonyl diimidazole in tetrahydrofuran,23 allowed us to
obtain the desired products 17–20 in good yields. Only for the
Ugi intermediate 13 it was possible to perform a chromato-
graphic separation of diastereoisomers (d.r. 13a : 13b
11.5 : 88.5) and achieve distinct compounds 17a and 17b, in
15% and 59% yield respectively. Clearly, as for the above
case of 2,5-diketopiperazines, also the cyclizations of Ugi
adducts 13a and 13b, to give the 2,6-diketopiperazines 17a
and 17b, are subject to quite diﬀerent steric restrictions.
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2,6-diketopiperazines 18–20 were obtained in good yields
(71–77%) and high d.e. (80–95%, from 1H NMR).
Finally, the two-step Ugi/cyclization strategy employing a
bifunctional amine was also applied to the synthesis of 3,4-
dihydropyrazin-2(1H)-one-based peptidomimetics 23–26
(Scheme 3). In this case, N-Cbz amino aldehydes 21 and 22
were employed in the Ugi reaction under usual conditions,
together with isocyanoacetates 3 and 4, 2,2-diethoxyethan-
amine and benzoic acid. The obtained Ugi products proved to
be highly unstable and therefore were not isolated, but directly
cyclized to give final compounds 23–26 in good overall yields.
In this case, all diastereoisomeric compounds 23a–26a and
Scheme 2 Reagents and conditions: (a) glycine benzylester, MeOH, rt, 2 h; then AcOH, 60 h. (b) Flash chrom. (c) H2, 10% Pd/C, MeOH, rt, 2 h; then
CDI, THF, 75 °C to rt, 4 h.
Scheme 1 Reagents and conditions: (a) p-anisidine, MeOH, rt, 2 h; then chloroacetic acid, 60 h. (b) Flash chrom. (c) Cs2CO3, 10% LiI, CH3CN, rt (or
60 °C for 5a to 9a), 20 h.
Organic & Biomolecular Chemistry Paper
This journal is © The Royal Society of Chemistry 2015 Org. Biomol. Chem., 2015, 13, 4993–5005 | 4995
Pu
bl
ish
ed
 o
n 
19
 M
ar
ch
 2
01
5.
 D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ita
 S
tu
di
 d
i M
ila
no
 o
n 
05
/0
5/
20
15
 1
4:
24
:2
4.
 
View Article Online
23b–26b could be easily separated by chromatography, allow-
ing us to estimate very high diastereoisomeric ratios, up to
b : a > 93 : 7.
In order to rationalize the stereochemical outcome of the
realized Ugi/cyclization processes, we relied on theoretical con-
formational analysis, NMR and CD spectra. Unfortunately, any
attempt to obtain crystals suitable for X-ray diﬀraction analysis
proved to be unsuccessful for all compounds in a wide range
of solvents and crystallization conditions.
We focused our analysis on compounds 9 and performed a
theoretical conformational search, which was run by the
Monte-Carlo algorithm and molecular mechanics (MMFF force
field), including all rotatable bonds and the puckering of
6-membered ring atoms. All structures thus obtained were geo-
metry-optimized with the DFT method at the B3LYP/6-31G(d)
level in vacuo. All structures obtained with population >1% at
room temperature were considered in the following. The calcu-
lations were run independently for the C-2(R) and C-2(S)
isomers of 9 (for atom numeration, see the structure in
Table 1).
The conformational analysis for the C-2(R) isomer revealed
a strong preference for conformations with anti orientation
between H-2 and H-15 and a pseudo-axial position of the C-2
appendage. Practically all populated structures at 300 K show a
consistent conformation around the C-2/C-15 bond (Fig. 1). In
this conformational family, aromatic ortho hydrogens are
expected to give NOE with the tBu group of the Boc moiety and
with NCH3, but not with CH3-17.
The conformational situation for the C-2(S) isomer is less
clear-cut. While the C-2 appendage occupies again a pseudo-
axial orientation, there are at least two main conformational
families, one (more favored, Fig. 2a) with gauche orientation
between H-2 and H-15 and a second (less favored, Fig. 2b) with
anti orientation. Although the NOE analysis is less straight-
forward, we can infer that aromatic ortho hydrogens are
expected to give a sizable NOE with CH3-17, and smaller or no
NOE with the Boc moiety and NCH3, respectively.
Comparison of the expected NOEs based on molecular
modeling with the experimentally observed data obtained
from ROESY correlation peaks (Table 1) oﬀers a strong indi-
cation to assign a C-2(S) configuration to the major diastereo-
isomer 9b and, conversely, a C-2(R) one to the minor
diastereoisomer 9a.
The configuration of the stereogenic carbon C-2 of the
major diastereoisomer 9b as C-2(S) was also studied by elec-
tronic circular dichroism (CD).24 The CD spectrum of 9b,
measured in acetonitrile solution, displays a series of relatively
weak bands above 185 nm (ESI†). CD spectra were calculated
with the TDDFT method on DFT-optimized input structures
for the two C-2(R) and C-2(S) isomers. Unfortunately, the two
isomers led to a similar sequence of bands which in both
cases reproduces the experimental spectrum of 9b; therefore a
Scheme 3 Reagents and conditions: (a) 2,2-diethoxyethanamine, MeOH, rt, 2 h; then benzoic acid, 60 h. (b) 50% TFA, DCM, rt, 24 h; then ﬂash
chrom.
Fig. 1 Superposition of the ﬁrst 8 low-energy structures of isomer
C-2(R) of compound 9, calculated at the B3LYP/6-31G(d) level.
Table 1 Predicted and experimentally-observed diagnostic NOEsa
NOE
Predicted
for
C-2(S)
Predicted
for
C-2(R)
Exp. for 9b
(major
diast.)
Exp. for 9a
(minor
diast.)
NCH3/H-2 m s w s
NCH3/H-27 — m — m
CH3-17/H-27 m/s — m —
tBu/H-27 w s — m
a Legend: s, strong; m, medium; w, weak; —, no NOE.
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safe discrimination based only on CD spectra is impossible
(ESI†). However, since CD spectroscopy does not contradict the
NMR results discussed above, we are confident of definitely
attributing the C-2(S) stereochemistry to the major diastereo-
isomer 9b and the C-2(R) one to the minor diastereoisomer 9a.
In accordance with this attribution, the observed diastereo-
selectivity in the Ugi reaction (Scheme 1) can be rationalized
by considering a Felkin–Ahn-like model, where the isocyano-
acetate reagent approaches towards the preformed iminium
intermediate from the less hindered side (Fig. 3), aﬀording
preferentially 5b over 5a.
The proposed model can also explain the trend of diastereo-
selectivity which was observed for strictly related 6–8 Ugi
products. Reasoning that in all described Ugi/cyclization
sequences (Schemes 2 and 3) the partial diastereocontrol is
likely to come from the addition of the isocyanoacetate reagent
to closely similar iminium intermediates, the reported
diastereoselective outcomes could be reasonably explained by
the application of Felkin–Ahn-like models similar to those
depicted in Fig. 3.
In order to assess our compounds as minimalist peptidomi-
metics, a computational study was performed. Structures a, b
and c were chosen as representative models of compounds 9b,
17b and 23b (Fig. 4), all characterized by the (S) stereochemical
configuration on the piperazine-based ring and by L-Ala-
derived side chains. Models a, b and c contain the minimalist
core provided with N-Ac and CO-NHMe terminal groups,
aimed to mimic the insertion of the peptidomimetic into a
putative peptide.
In this approach, the spatial mobility of the side chains
connected to the central hetero-aromatic ring of the three
models was analyzed by minimizing, equilibrating and heating
up the starting models to 300 K, 700 K and 1000 K for a short
period (2 ns). Finally, passing through an intermediate equili-
bration step at 700 K, 20 ns of MD simulations at room temp-
erature (300 K) were performed.5b The algorithm of the
AMBER12 package25 was executed for the entire calculation of
each model, using the GB implicit water solvent model.26
A frame every 10 ps of MD simulations was recorded, acquiring
2800 conformational states of each mode (see the Experi-
mental section). Analyzing the dihedral angle fluctuation
(arrows in Fig. 4) over the obtained trajectories, the diﬀerent
families of conformations for models a, b and c were
recognized.
Furthermore, the geometries representing those families of
conformations were energy minimized by GAUSSIAN0927 at
the quantum-mechanics DFT/B3LYP/6-31g(d)/CPCM-water
level of calculation. The application of the Boltzmann equation
provided the conformers distribution percentage (tables in
Fig. 4). Finally, in order to establish the correspondence of
Cβ–Cβ distances for peptidomimetics models a, b and c
Fig. 2 Superposition of the ﬁrst 9 low-energy structures of isomer
C-2(S) of compound 9, calculated at the B3LYP/6-31G(d) level (a, more
favored; b, less favored).
Fig. 3 Proposed model for the diastereoselective formation of 5b in
Scheme 1.
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with common secondary structures, the distances between
the Cβ atoms of the side chains were measured (tables in
Fig. 4).
The results indicate that model b, in comparison with a
and c, possesses the highest number of thermodynamically
accessible conformers at room temperature. This can be due
to the minor steric hindrance of the N-substituent on the
piperazine core, with the acetyl group in model b allowing
major mobility for the vicinal side chains in comparison with
the 4-methoxy-phenyl and benzoyl groups of models a and c.
Comparing the Cβ–Cβ distances measured in the lowest
energy conformers of a, b and c with those reported by
Burgess and co-workers5 for typical secondary structures, we
were able to predict the secondary structures potentially
mimicked by our compounds (Table 2). Model compounds a
and c can assume conformations compatible with secondary
structures like α-helix, β-sheet (anti-parallel) and γ-turn
(classic). In contrast, the populated conformers of model b
may mimic all the secondary structures reported in Table 2.
Moreover, it has to be underlined that model c mimics pre-
dominantly the α-helix and the β-sheet (anti-parallel) second-
ary structures. This is due to an internal hydrogen-bond
stabilizing nearly only one structural geometry (Fig. 4).
Because of our particular interest in cancer drug resistance,
all compounds have been preliminarily evaluated for their
antiproliferative eﬀects on two diﬀerent hepatocellular carci-
noma (HCC) cellular lines, namely Huh7 (well diﬀerentiated
cells) and Mahlavu (PTEN deficient poorly diﬀerentiated cells),
for which diﬀerentiation versus resistance ability seems to be
strongly correlated with well defined types of PPIs.28 A signifi-
cant antiproliferative eﬀect, in the micromolar range (see
ESI†), has been observed for 12 and 25b and deserves further
studies, which are currently in progress.
Fig. 4 Above: 2D structures of models a, b and c with their low energy conformers 3D images. Blue dotted line on model c represents the internal
hydrogen-bond. Below: tables reporting the Boltzmann distributions and the Cβ–Cβ distances.
Table 2 Correspondence of Cβ–Cβ distances for models a, b and c
with those reported for the most common peptide secondary structures.
Numbers highlighted by color represent the conformer percentage
showing the speciﬁc Cβ–Cβ distance/secondary structure. They were
retrieved from the Boltzmann distribution shown in Fig. 4
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Conclusion
We have demonstrated the feasibility of a two-step multi-
component synthesis of three complex, yet structurally distinct,
piperazine-based scaﬀolds, in which bifunctional substrates
mediate highly selective outcomes based on Ugi/cyclization
sequences. All scaﬀolds are characterized by the presence of
L-Ala and/or L-Phe-derived amino acid side chains and have
been demonstrated to act as minimalist peptidomimetics, able
to mimic a range of secondary structures and therefore poten-
tially useful for the synthesis of small-molecule PPI
modulators. Preliminary biological evaluation of cancer resist-
ant cellular lines has revealed a promising antiproliferative
activity for selected compounds, for which further investi-
gation is currently underway.
Experimental section
General information
All commercial materials (Aldrich, Fluka) were used without
further purification. All solvents were of reagent grade or
HPLC grade. All reactions were carried out under a nitrogen
atmosphere unless otherwise noted. All reactions were moni-
tored by thin layer chromatography (TLC) on precoated silica
gel 60 F254; spots were visualized with UV light or by treat-
ment with a 1% aqueous KMnO4 solution. Products were puri-
fied by flash chromatography on silica gel 60 (230–400 mesh).
1H NMR spectra and 13C NMR spectra were recorded on 300
and 400 MHz spectrometers. Chemical shifts are reported in
parts per million relative to the residual solvent. 13C NMR
spectra have been recorded using the APT pulse sequence.
Multiplicities in 1H NMR are reported as follows: s = singlet,
d = doublet, t = triplet, m = multiplet, br s = broad singlet. High-
resolution MS spectra were recorded with an FT-ICR (Fourier
Transform Ion Cyclotron Resonance) instrument, equipped
with an ESI source. UV-Vis spectra were recorded with a Jasco
V-650 spectrophotometer. CD spectra were recorded with a
JASCO J-715 spectropolarimeter; the conditions are reported in
the legend of Fig. 2.
General procedure for the synthesis of compounds 5–8
Aldehyde (1 or 2) (1.0 mmol, 1 eq.) was dissolved in 1 mL of
dry methanol under nitrogen, 4-methoxy aniline (1.0 mmol,
123 mg, 1 eq.) was added and the resulting mixture was kept
under stirring for 2 h at room temperature. 2-Chloroacetic acid
(1.0 mmol, 94.5 mg, 1 eq.) and isocyanide (3 or 4) (1.2 mmol,
1.2 eq.) were sequentially added and the reaction was stirred
for an additional 60 h at room temperature. The resulting
mixture was then concentrated under reduced pressure, to give
a residue which was purified by flash chromatography (FC) as
indicated below.
(S)-Methyl-2-((2R,3S)-3-((tert-butoxycarbonyl)(methyl)amino)-
2-(2-chloro-N-(4-methoxyphenyl)acetamido)butanamido)propanoate,
5a and (S)-methyl-2-((2S,3S)-3-((tert-butoxycarbonyl)(methyl)-
amino)-2-(2-chloro-N-(4-methoxyphenyl)acetamido)butanamido)-
propanoate, 5b. Prepared according to the above general pro-
cedure from aldehyde 1 and isocyanide 3; FC: ethyl acetate–
n-hexane, 1 : 1.5; yield: 5a (97 mg, 19%), 5b (356 mg, 71%). 5a:
colorless oil; Rf 0.21 (1.5 : 1 n-hexane–EtOAc); [α]
30
D −16.3 (c 0.5,
CHCl3);
1H NMR (300 MHz, CD3CN, 1 : 1 mixture of rotamers)
δ 7.38–7.08 (m, 3H), 6.95 (d, J = 8.8 Hz, 2H), 4.45–4.09 (br, s,
1H), 3.85 (br, s, 2H), 3.81 (s, 3H), 3.82–3.75 (m, 1H), 3.69 (s,
1.5H), 3.71–3.63 (m, 1H), 3.67 (br, s, 1.5H), 2.65 (s, 3H),
1.46–1.31 (m, 12H), 1.27 (br, d, J = 6.8 Hz, 3H); 13C NMR
(75 MHz, CD3CN) δ 178.1, 173.0 (2C), 165.4, 160.2, 136.5,
136.2, 135.5, 120.0, 119.8, 84.8 and 84.6 (1C), 60.6, 60.5, 57.2,
53.5, 53.4, 48.5, 48.3, 34.3, 33.0 (3C), 22.2 and 21.9 (1C), 19.7
and 19.6 (1C); HRMS (ESI) calcd for C23H34ClN3NaO7
+ [MNa]+
522.1977, found 522.1983. 5b: colorless oil; Rf 0.18 (1.5 : 1
n-hexane–EtOAc); [α]30D +8.5 (c 0.5, CHCl3);
1H NMR (300 MHz,
CD3CN, 1 : 1 mixture of rotamers) δ 7.40–7.08 (br, m, 1H), 7.20
(m, 2H), 6.95 (d, J = 9.1 Hz, 2H), 4.41–4.12 (br, m, 1H), 3.86
(br, s, 2H), 3.81 (s, 3H), 3.79 (m, 1H), 3.67 (br, s, 1.5H), 3.65
(m, 1H), 3.64 (s, 1.5H), 2.67 (s, 3H), 1.38 (s, 9H), 1.32 (m, 3H),
1.27 (br, d, J = 6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 173.5
and 173.4 (1C), 169.4–168.7 (2C), 160.6, 157.0 and 156.8 (1C),
131.4, 130.8, 130.2, 115.7, 115.5, 81.0 and 80.6 (1C), 56.1 (2C),
53.0, 52.9, 48.9 (2C), 43.1 and 43.0 (1C), 29.1 (4C), 18.2, 16.1;
HRMS (ESI) calcd for C23H34ClN3NaO7
+ [MNa]+ 522.1977,
found 522.1961.
(2S)-Methyl 2-((3S)-3-((tert-butoxycarbonyl)(methyl)amino)-
2-(2-chloro-N-(4-methoxyphenyl)acetamido)butanamido)-3-
phenylpropanoate, 6. Prepared according to the above general
procedure from aldehyde 1 and isocyanide 4; FC: ethyl acetate–
n-hexane, 1 : 1.5; yield 524 mg, (91%) as an inseparable
mixture of diastereoisomers (d.e. 50%, NMR analysis): pale
yellow oil; Rf 0.24 (1.5 : 1 n-hexane–EtOAc);
1H NMR (300 MHz,
CD3CN, rotameric mixture of a mixture of diastereoisomers)
δ 7.47–6.99 (m, 8H), 6.89 (br, d, J = 8.8 Hz, 2H), 4.80–4.40 (br,
m, 1H), 3.81 (br, s, 2H), 3.80–3.74 (m, 4H), 3.69 (s, 0.5H),
3.69–3.63 (m, 3.5H), 3.24–3.05 (br, m, 1H), 3.03–2.80 (br, m,
1H), 2.62 (s, 2.75H), 2.58 (s, 0.25H), 1.36 (s, 9H), 1.28–1.21 (m,
3H); HRMS (ESI) calcd for C29H38ClN3NaO7
+ [MNa]+ 598.2290,
found 598.2305.
(2S)-Methyl 2-((3S)-3-((tert-butoxycarbonyl)(methyl)amino)-
2-(2-chloro-N-(4-methoxyphenyl)acetamido)-4-phenylbutan-
amido)propanoate, 7. Prepared according to the above general
procedure from aldehyde 2 and isocyanide 3; FC: ethyl acetate–
n-hexane, 1 : 1.5; yield 501 mg, (87%) as an inseparable
mixture of diastereoisomers (d.e. 56%, NMR analysis): pale
yellow oil; Rf 0.22 (1.5 : 1 n-hexane–EtOAc);
1H NMR (300 MHz,
CD3CN, rotameric mixture of a mixture of diastereoisomers)
δ 7.40–7.04 (m, 8.4H), 6.96 (br, d, J = 8.4 Hz, 1.6H), 4.59–4.40
(br, m, 1H), 3.93–3.64 (m, 10H), 3.33–2.87 (m, 1H), 2.80 (s,
0.66H), 2.76 (s, 2.34H), 2.64 (m, 1H), 1.52–1.26 (m, 12H);
HRMS (ESI) calcd for C29H38ClN3NaO7
+ [MNa]+ 598.2290,
found 598.2305.
(2S)-Methyl 2-((3S)-3-((tert-butoxycarbonyl)(methyl)amino)-
2-(2-chloro-N-(4-methoxyphenyl)acetamido)-4-phenylbutan-
amido)-3-phenylpropanoate, 8. Prepared according to the
above general procedure from aldehyde 2 and isocyanide 4;
Organic & Biomolecular Chemistry Paper
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FC: ethyl acetate–n-hexane, 1 : 1.5; yield 573 mg, (88%) as an
inseparable mixture of diastereoisomers (d.e. 51%, NMR analy-
sis): oil; Rf 0.44 (1.5 : 1 n-hexane–EtOAc);
1H NMR (400 MHz,
CDCl3, rotameric mixture of a mixture of diastereoisomers) δ
7.38–7.06 (m, 11.4H), 7.02–6.80 (br, m, 3.6H), 5.05–4.67 (br, m,
1H), 3.93–3.58 (m, 10H), 3.32–3.18 (m, 1H), 3.05–2.86 (m, 2H),
2.78 (s, 0.75H), 2.75 (s, 2.25H), 2.65 (m, 1H), 1.40 (m, 9H);
HRMS (ESI) calcd for C35H42ClN3NaO7
+ [MNa]+ 674.2603,
found 674.2622.
General procedure for the synthesis of compounds 9–12
To a solution of the Ugi product (5a, 5b, 6, 7 or 8) (0.5 mmol,
1 eq.) in dry acetonitrile (4.5 mL) under nitrogen, cesium car-
bonate (1 mmol, 326 mg, 4 eq.) and LiI (0.05 mmol, 7 mg, 0.1
eq.) were added, and the mixture was stirred for 20 h at room
temperature (or at 60 °C, for 5a). The mixture was quenched
with satd aq. NH4Cl (20 mL) and extracted with EtOAc (3 ×
20 mL). The combined organic layers were washed with brine,
dried over Na2SO4 and concentrated under reduced pressure,
to give a residue, which was purified by flash chromatography
(FC) as indicated below.
(S)-Methyl 2-((R)-3-((S)-1-((tert-butoxycarbonyl)(methyl)-
amino)ethyl)-4-(4-methoxyphenyl)-2,5-dioxopiperazin-1-yl)pro-
panoate, 9a. Prepared according to the above general pro-
cedure from 5a; FC: ethyl acetate–n-hexane, 1 : 1.5; yield: 37 mg
(16%); colorless oil; Rf 0.18 (1.5 : 1 n-hexane–EtOAc);
[α]30D −12.7 (c 0.5, CHCl3); 1H NMR (300 MHz, CD3CN) δ 7.43
(br, m, 2H), 6.98 (d, J = 8.8 Hz, 2H), 5.03 (q, J = 7.0 Hz, 1H),
4.63 (br, m, 1H), 4.34 (br, m, 1H), 4.30 (br, d, J = 16.6 Hz, 1H),
3.88 (d, J = 16.7 Hz, 1H), 3.83 (s, 3H), 3.73 (s, 3H), 2.67 (s, 3H),
1.45 (s, 9H), 1.44 (d, J = 7.0 Hz, 3H), 1.24 (br, d, J = 7.5 Hz, 3H);
13C NMR (100 MHz, CD3CN) δ 172.2, 168.4, 165.0 (2C), 160.7,
133.9, 131.4 (2C), 130.0, 115.3 (2C), 80.9, 68.5, 55.8, 52.5 (2C),
49.1 and 48.9 (1C), 48.0, 28.3 (3C), 17.4, 14.2; HRMS (ESI)
calcd for C23H33N3NaO7
+ [MNa]+ 486.2211, found 486.2227.
(S)-Methyl 2-((S)-3-((S)-1-((tert-butoxycarbonyl)(methyl)-
amino)ethyl)-4-(4-methoxyphenyl)-2,5-dioxopiperazin-1-yl)pro-
panoate, 9b. Prepared according to the above general pro-
cedure from 5b; FC: ethyl acetate–n-hexane, 1 : 1.5; yield:
176 mg (76%); colorless oil; Rf 0.16 (1.5 : 1 n-hexane–EtOAc);
[α]30D +24.2 (c 1.0, MeOH);
1H NMR (400 MHz, CD3CN) δ 7.36
(br, d, J = 8.9 Hz, 2H), 6.98 (d, J = 9.2 Hz, 2H), 5.12 (q, J = 7.3
Hz, 1H), 4.73 (br, m, 1H), 4.29 (d, J = 16.7 Hz, 1H), 4.27 (br, m,
1H), 3.88 (br, d, J = 16.7 Hz, 1H), 3.83 (s, 3H), 3.69 (s, 3H), 2.68
(s, 3H), 1.46 (d, J = 7.3 Hz, 3H), 1.45 (s, 9H), 1.16 (br, d, J = 7.0
Hz, 3H); 13C NMR (100 MHz, CD3CN) δ 172.2, 165.9, 164.9,
159.1, 133.9, 130.0, 129.2 (2C), 114.6 (2C), 80.2, 68.4, 55.9,
52.7, 52.1, 51.5, 48.0, 29.5, 28.3 (3C), 16.5, 13.8; HRMS (ESI)
calcd for C23H33N3NaO7
+ [MNa]+ 486.2211, found 486.2216.
(S)-Methyl-2-((S)3-((S)-1-((tert-butoxycarbonyl)(methyl)amino)-
ethyl)-4-(4-ethoxyphenyl)-2,5-dioxopiperazin-1-yl)-3-phenyl-
propanoate, 10. Prepared according to the above general pro-
cedure from 6; FC: ethyl acetate–n-hexane, 3 : 7; yield: 124 mg
(46%); wax; Rf 0.15 (7 : 3 n-hexane–EtOAc); [α]
22
D −55.2 (c 1.0,
CHCl3);
1H NMR (400 MHz, CDCl3) δ 7.34–7.23 (m, 3H),
7.21–7.16 (m, 2H), 7.14–7.05 (m, 2H), 6.90 (d, J = 8.9 Hz, 2H),
5.68 (dd, J = 11.4, 5.1 Hz, 1H), 4.70 (br, m, 1H), 4.41 (d, J =
17.3 Hz, 1H), 4.03 (d, J = 17.3 Hz, 1H), 3.88 (br, m, 1H), 3.81 (s,
3H), 3.80 (s, 3H), 3.40 (dd, J = 14.4 and 5.1 Hz, 1H), 2.99 (dd,
J = 14.4, 11.4 Hz, 1H), 2.68 (s, 3H), 1.46 (s, 9H), 1.17 (d, J =
7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 170.7, 166.8, 164.7,
159.3, 156.7, 136.1, 133.0, 129.8 (2C), 129.4 (2C), 129.2 (2C),
127.7, 115.0 (2C), 80.9, 69.0, 56.6, 56.1, 53.0, 51.9, 47.6, 35.5,
29.9, 29.1 (3C), 17.1; HRMS (ESI) calcd for C29H37N3NaO7
+
[MNa]+ 562.2524, found 562.2509.
(S)-Methyl-2-((S)3-((S)-1-((tert-butoxycarbonyl)(methyl)amino)-
2-phenylethyl)-4-(4-methoxyphenyl)-2,5-dioxopiperazin-1-yl)-
propanoate, 11. Prepared according to the above general pro-
cedure from 7; FC: ethyl acetate–n-hexane, 1 : 1.5; yield:
178 mg (66%); pale yellow oil; Rf 0.15 (1.5 : 1 n-hexane–EtOAc);
[α]30D +2.2 (c 0.5, CHCl3);
1H NMR (400 MHz, CDCl3) δ 7.35–7.24
(m, 2H), 7.24–7.12 (m, 3H), 7.12–7.05 (m, 2H), 6.92 (d, J =
8.6 Hz, 2H), 5.29 (q, J = 7.1 Hz, 1H), 4.97 (br, m, 1H), 4.43–4.30
(m, 2H), 3.99 (d, J = 16.7 Hz, 1H), 3.83 (s, 3H), 3.74 (s, 3H),
3.08 (br, m, 1H), 2.77 (br, m, 2H), 2.67 (s, 3H), 1.47 (d, J =
7.1 Hz, 3H), 1.44 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 171.8,
166.0, 164.7, 159.3, 157.1, 137.7, 132.9, 129.6 (2C), 129.1 (2C),
128.8 (2C), 127.2, 115.1 (2C), 81.0, 67.3, 57.7, 56.1, 52.3, 51.7,
47.6, 36.9, 30.8, 28.9 (3C), 14.5; HRMS (ESI) calcd for
C29H37N3NaO7
+ [MNa]+ 562.2524, found 562.2536.
(2S)-Methyl-2-((S)3-((S)-1-((tert-butoxycarbonyl)(methyl)amino)-
2-phenylethyl)-4-(4-methoxyphenyl)-2,5-dioxopiperazin-1-yl)-
3-phenylpropanoate, 12. Prepared according to the above
general procedure from 8; FC: ethyl acetate–n-hexane, 3 : 7;
yield: 151 mg (56%); yellow oil; Rf 0.21 (7 : 3 n-hexane–EtOAc);
[α]31D = −74.7 (c 1.0, MeOH); 1H NMR (400 MHz, CDCl3) δ
7.35–7.23 (m, 4H), 7.23–7.18 (m, 2H), 7.18–7.11 (m, 2H),
7.10–6.99 (m, 4H), 6.88 (d, J = 8.8 Hz, 2H), 5.73 (dd, J = 11.3
and 5.3 Hz, 1H), 4.94 (br, m, 1H), 4.40 (d, J = 17.2 Hz, 1H),
4.05 (d, J = 17.2 Hz, 1H), 4.03 (br, m, 1H), 3.83 (s, 3H), 3.81 (s,
3H), 3.44 (dd, J = 14.4 and 5.3 Hz, 1H), 3.03 (dd, J = 14.4 and
11.3 Hz, 1H), 3.05–2.77 (m, 2H), 2.64 (s, 3H), 1.40 (s, 9H); 13C
NMR (100 MHz, CDCl3) δ 170.6, 166.8, 164.7, 159.5, 157.0,
137.5, 136.1, 132.2, 129.7 (2C), 129.4–129.0 (8C), 127.8, 127.1
(2C), 115.1, 80.9, 67.1, 56.7, 56.1 (2C), 53.1, 47.4, 36.7, 35.4,
30.3, 28.9 (3C); HRMS (ESI) calcd for C35H41N3NaO7
+ [MNa]+
638.2837, found 638.2847.
General procedure for the synthesis of compounds 13–16
Aldehyde (1 or 2) (1.0 mmol, 1 eq.) was dissolved in 1 mL of
dry methanol under nitrogen, O-benzyl glycine (1.0 mmol,
165 mg, 1 eq.) was added and the resulting mixture was kept
under stirring for 2 h at room temperature. Acetic acid
(1.0 mmol, 60 mg, 1 eq.) and isocyanide (3 or 4) (1.2 mmol, 1.2
eq.) were sequentially added and the reaction was stirred for
an additional 60 h at room temperature. The resulting mixture
was diluted with water (10 mL) and extracted with EtOAc (3 ×
5 mL). The combined organic layers were dried over Na2SO4
and the solvent was removed under reduced pressure to aﬀord
the crude Ugi product, which was purified by flash chromato-
graphy (FC) as indicated below.
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(S)-Methyl 2-((2R,3S)-2-(N-(2-(benzyloxy)-2-oxoethyl)acet-
amido)-3-((tert-butoxycarbonyl)(methyl)amino)butanamido)-
propanoate, 13a and (S)-methyl 2-((2S,3S)-2-(N-(2-(benzyloxy)-2-
oxoethyl)acetamido)-3-((tert-butoxycarbonyl)(methyl)amino)-
butanamido)propanoate, 13b. Prepared according to the
above general procedure from aldehyde 1 and isocyanide 3;
FC: ethyl acetate–n-hexane, 1 : 1.5; yield: 13a (35 mg, 7%), 13b
(276 mg, 54%). 13a: amber oil; Rf 0.18 (1 : 1.5 n-hexane–EtOAc);
[α]30D −3.4 (c 0.5, CHCl3); 1H NMR (300 MHz, CDCl3,
1 : 1 mixture of rotamers) δ 7.34 (br, m, 5H), 6.62–6.27 (br, m,
1H), 5.16–5.08 (m, 2H), 5.06 (br, m, 1H), 4.79–4.61 (br, m, 1H),
4.47 (d, J = 19.5 Hz, 0.5H), 4.45 (d, J = 19.5 Hz, 0.5H), 4.23 (br,
m, 1H), 4.01 (br, d, J = 19.5 Hz, 1H), 3.72 (s, 1.5), 3.71 (s, 1.5),
2.62 (br, s, 3H), 1.98 (br, s, 1.5), 1.95 (s, 1.5), 1.42 (s, 9H), 1.36
(d, J = 6.8 Hz, 3H), 1.14 (br, m, 3H); 13C NMR (75 MHz, CDCl3,
mixture of rotamers) δ 173.0 and 172.9 (1C), 172.6 and 172.4
(1C), 168.2 and 168.1 (1C), 167.8, 155.8, 135.4, 128.6–128.2
(5C), 79.4, 66.9, 57.4–56.0 (br, 1C), 52.3, 48.4, 48.1, 47.1 and
46.7 (br, 1C), 28.7, 28.4 (3C), 21.6, 18.0, 15.2 and 14.8 (1C);
HRMS (ESI) calcd for C25H37N3NaO8
+ [MNa]+ 530.2473, found
530.2455. 13b: Rf 0.15 (1 : 1.5 n-hexane–EtOAc); [α]
30
D +8.8 (c 0.5,
CHCl3);
1H NMR (300 MHz, CDCl3, 1 : 1 mixture of confor-
mers) δ 7.35 (br, m, 5H), 6.65–6.28 (br, m, 1H), 5.17 (br, m,
3H), 4.51–4.19 (br, m, 4H), 3.70 (s, 1.5), 3.68 (s, 1.5), 2.81 (s,
3H), 2.03 (br, s, 3H), 1.42 (s, 9H), 1.32 (d, J = 6.8 Hz, 3H), 1.15
(d, J = 6.8 Hz, 1.5H), 1.12 (d, J = 6.8 Hz, 1.5H); 13C NMR
(75 MHz, CDCl3, mixture of rotamers) δ 172.4–172.0 (2C),
169.6, 168.9 and 168.8 (1C), 155.4 and 155.2 (1C), 135.4 and
135.2 (1C), 129.1–128.0 (5C), 80.3, 67.4 and 67.2 (1C), 59.6,
52.6, 48.5, 48.1, 47.8, 29.7, 28.4 (3C), 21.6, 17.6, 15.7 and 15.3
(1C); HRMS (ESI) calcd for C25H37N3NaO8
+ [MNa]+ 530.2473,
found 530.2482.
(2S)-Methyl-2-((3S)-2-(N-(2-(benzyloxy)-2-oxoethyl)acetamido)-
3-((tert-butoxycarbonyl)(methyl)amino)butanamido)-3-phenyl-
propanoate, 14. Prepared according to the above general pro-
cedure from aldehyde 1 and isocyanide 4; FC: ethyl acetate–n-
hexane, 1 : 1; yield: 344 mg (59%), as an inseparable mixture of
diastereoisomers (d.e. 80%, NMR analysis): pale yellow oil; Rf
0.27 (1 : 1 n-hexane–EtOAc); 1H NMR (300 MHz, CDCl3, rota-
meric mixture of two diastereoisomers) δ 7.41–7.03 (m, 11H),
5.28–5.10 (m, 3H), 4.78 (br, m, 0.9H), 4.78–3.93 (m, 3.1H), 3.68
(s, 0.3H), 3.65 (s, 2.7H), 3.09 (br, m, 1H), 3.01 (m, 1H), 2.75
(br, s, 2.7H), 2.58 (s, 0.3H), 1.97 (br, m, 3H), 1.42 (s, 0.9H),
1.39 (s, 8.1H), 1.09 (br, d, J = 6.8 Hz, 3H); HRMS (ESI) calcd for
C31H41N3NaO8
+ [MNa]+ 606.2786, found 606.2800.
(2S)-Methyl-2-((3S)-2-(N-(2-(benzyloxy)-2-oxoethyl)acetamido)-
3-((tert-butoxycarbonyl)(methyl)amino)-4-phenylbutanamido)-
propanoate, 15. Prepared according to the above general
procedure from aldehyde 2 and isocyanide 3; FC: ethyl acetate–
n-hexane, 1.5 : 1; yield: 256 mg (44%), as an inseparable
mixture of diastereoisomers (d.e. 84%, NMR analysis): pale
yellow oil; Rf 0.20 (1 : 5 n-hexane–EtOAc);
1H NMR (300 MHz,
CDCl3, rotameric mixture of two diastereoisomers) δ
7.46–7.04 (m, 11H), 5.34–5.10 (m, 3H), 4.88 (br, m, 0.9H),
4.62–3.91 (m, 3.1H), 3.73 (s, 0.24H), 3.65 (s, 2.76H), 3.32 (br,
m, 1H), 3.07 (br, m, 1H), 2.81 (br, s, 2.76H), 2.65 (s, 0.24H),
2.00 (br, s, 2.76H), 1.97 (s, 0.24H), 1.43 (br, s, 9H), 1.36 (br, m,
3H); HRMS (ESI) calcd for C31H41N3NaO8
+ [MNa]+ 606.2786,
found 606.2761.
(2S)-Methyl-2-((3S)-2-(N-(2-(benzyloxy)-2-oxoethyl)acetamido)-
3-((tert-butoxycarbonyl)(methyl)amino)-4-phenylbutanamido)-
3-phenylpropanoate, 16. Prepared according to the above
general procedure from aldehyde 2 and isocyanide 4; FC: ethyl
acetate–n-hexane, 1 : 1.5; yield: 587 mg (89%), as an insepar-
able mixture of diastereoisomers (d.e. 72%, NMR analysis):
colorless oil; Rf 0.18 (1.5 : 1 n-hexane–EtOAc);
1H NMR
(300 MHz, CDCl3, rotameric mixture of two diastereoisomers)
δ 7.43–7.01 (m, 16H), 5.29–5.09 (m, 3H), 4.88 (m, 0.86H), 4.74
(m, 0.14H), 4.64–4.43 (m, 1.86H), 4.29 (m, 0.14H), 4.01 (br, d,
J = 16.6 Hz, 1H), 3.74 (s, 0.24H), 3.67 (s, 1.26H), 3.65 (s, 1.5H),
3.54–2.84 (m, 4H), 2.70 (s, 2.52H), 2.63 (s, 0.48H), 2.07 (s,
0.24H), 1.98 (s, 1.5H), 1.95 (s, 1.26H), 1.41 (s, 9H); HRMS (ESI)
calcd for C37H45N3NaO8
+ [MNa]+ 682.3099, found 682.3114.
General procedure for the synthesis of compounds 17–20
Palladium (10 wt% on carbon, 70 mg) was added to a solution
of the Ugi product (13a, 13b, 14, 15 or 16) (0.30 mmol, 1 eq.)
in methanol (3 mL). The reaction mixture was degassed
in vacuo, placed under an atmosphere of H2 (g), and stirred in
the dark at rt for 2 h. The mixture was filtered through a pad
of Celite eluting with methanol (10 mL), and the combined
organic layers were concentrated in vacuo to give the crude
carboxylic acid intermediate, which was directly used in the
next step, as follows. 1,1′-Carbonyl diimidazole (0.30 mmol,
127 mg, 1 eq.) was added to a solution of the crude carboxylic
acid in dry tetrahydrofuran (3 mL), under nitrogen, and the
resulting mixture was refluxed for 60 min and then stirred for
an additional 3 h at room temperature. The solvent was
removed under reduced pressure to give a residue which was
partitioned between CHCl3 (10 mL) and 1 M HCl (10 mL). The
aqueous phase was extracted with CHCl3 (3 × 10 mL) and the
combined organic layers were washed with H2O, dried over
Na2SO4 and concentrated in vacuo to aﬀord the crude product,
which was purified by flash chromatography (FC), as indicated
below.
(S)-Methyl 2-((R)-4-acetyl-3-((S)-1-((tert-butoxycarbonyl)-
(methyl)amino)ethyl)-2,6-dioxopiperazin-1-yl)propanoate, 17a.
Prepared according to the above general procedure from 13a;
FC: ethyl acetate–n-hexane, 7 : 3; yield: 18 mg (15%); colorless
oil; Rf 0.33 (3 : 7 n-hexane–EtOAc); [α]
30
D −15.6 (c 0.5, CHCl3); 1H
NMR (300 MHz, CDCl3) δ 4.63–3.90 (m, 5H), 3.72 (br, s, 3H),
2.82 (br, s, 3H), 2.08 (br, s, 3H), 1.45 (s, 9H), 1.37 (br, d, J = 6.8
Hz, 3H), 1.12 (br, d, J = 6.8 Hz, 3H); 13C NMR (100 MHz,
CDCl3) δ 170.1, 169.1, 167.0, 166.5 and 166.4 (1C), 155.9, 80.5,
55.0, 52.5, 49.5, 48.8, 46.5, 29.0, 28.3 (3C), 21.1, 15.5 and 15.4
(1C), 14.2 and 13.9 (1C); HRMS (ESI) calcd for C18H29N3NaO7
+
[MNa]+ 422.1898, found 422.1924.
(S)-Methyl 2-((S)-4-acetyl-3-((S)-1-((tert-butoxycarbonyl)-
(methyl)amino)ethyl)-2,6-dioxopiperazin-1-yl)propanoate, 17b.
Prepared according to the above general procedure from 13b;
FC: ethyl acetate–n-hexane, 7 : 3; yield: 71 mg (59%); colorless
oil; Rf 0.29 (3 : 7 n-hexane–EtOAc); [α]
30
D +39.9 (c 0.5, CHCl3);
1H
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NMR (400 MHz, CDCl3, mixture of conformers 1.5 : 1) δ 5.36
(br, d, J = 9.9 Hz, 1H), 5.19 (m, 1H), 4.72 (m, 1H), 4.57 (d, J =
18.7 Hz, 0.6H), 4.52 (d, J = 18.7 Hz, 0.4H), 4.29 (d, J = 18.7 Hz,
0.4H), 4.24 (d, J = 18.7 Hz, 0.6H), 3.68 (s, 1.8H), 3.67 (s, 1.2H),
2.82 (br, s, 1.8H), 2.80 (s, 1.2H), 2.23–2.15 (m, 3H), 1.52 (d, J =
7.0 Hz, 1.8H), 1.45 (d, J = 7.0 Hz, 1.2H), 1.44–1.38 (m, 9H), 1.19
(br, d, J = 6.5 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 169.9,
169.0, 167.0, 166.4, 156.1, 80.2, 54.7, 52.4, 49.4, 48.7, 46.8,
28.9, 28.3 (3C), 21.4, 15.5, 14.1; HRMS (ESI) calcd for
C18H29N3NaO7
+ [MNa]+ 422.1898, found 422.1917.
(2S)-Methyl-2-(4-acetyl-3-((S)-1-((tert-butoxycarbonyl)(methyl)-
amino)ethyl)-2,6-dioxopiperazin-1-yl)-3-phenylpropanoate,
18. Prepared according to the above general procedure from
14; FC: ethyl acetate–n-hexane, 1.5 : 1; yield: 105 mg (74%), as
an inseparable mixture of diastereoisomers (d.e. 80%, NMR
analysis); foam; Rf 0.36 (1 : 1.5 n-hexane–EtOAc);
1H NMR
(400 MHz, CD3CN, a mixture of two diastereoisomers)
δ 7.34–7.03 (m, 5H), 5.56–5.37 (br, m, 1.9H), 4.59 (br, m, 1H),
4.57 (d, J = 18.7 Hz, 1H), 4.83–4.11 (m, 2H), 3.66 (br, s, 3H),
3.43 (m, 1H), 3.17–2.99 (m, 1H), 2.79 (s, 0.3H), 2.77 (s, 2.7H),
2.23 (s, 2.7H), 2.14 (s, 0.3H), 1.42 (s, 9H), 1.14 (m, 3H); 13C
NMR (101 MHz, CD3CN), δ 170.2–167.8 (4C), 156.3 and 156.0
(1C), 138.2, 129.8 (2C), 129.0 (2C), 127.3 (1C), 80.4, 54.2–53.8
(2C), 52.8, 51.4 and 50.9 (1C), 47.1 and 46.9 (1C), 34.7, 30.4,
28.4 (3C), 21.3, 15.2 and 14.8 (1C); HRMS (ESI) calcd for
C24H33N3NaO7
+ [MNa]+ 498.5239, found 498.5223.
(2S)-Methyl-2-(4-acetyl-3-((S)-1-((tert-butoxycarbonyl)(methyl)-
amino)-2-phenylethyl)-2,6-dioxopiperazin-1-yl)propanoate, 19.
Prepared according to the above general procedure from 15;
FC: ethyl acetate–n-hexane, 1 : 1.5; yield: 110 mg (77%), as an
inseparable mixture of diastereoisomers (d.e. 95%, NMR analy-
sis); foam; Rf 0.13 (1.5 : 1 n-hexane–EtOAc);
1H NMR (400 MHz,
CD3CN, 1 : 1 rotameric mixture) δ 7.37–7.19 (m, 5H), 5.50(m,
1H), 5.25 (m, 1H), 5.02–4.58 (m, 2H), 4.41 (d, J = 18.6 Hz, 1H),
3.66 (s, 1.5H), 3.65 (s, 1.5H), 3.04–2.77 (br, m, 2H), 2.79 (s,
3H), 2.18 (s, 3H), 1.45 (d, J = 6.9 Hz, 1.5H), 1.44 (d, J = 6.9 Hz,
1.5H), 1.35 (br, m, 9H); 13C NMR (100 MHz, CD3CN), δ 170.7
and 170.1 (1C), 170.0–169.7 (1C), 169.1, 167.5, 156.2 and 156.1
(1C), 137.8, 129.1, 128.9, 128.3 (2C), 126.5 and 126.4 (1C), 79.7
and 79.4 (1C), 56.4, 54.9 and 54.5 (1C), 52.0, 48.3, 46.7, 34.4
and 34.3 (1C), 27.9, 27.5 (3C), 20.9, 13.6 and 13.4 (1C); HRMS
(ESI) calcd for C24H33N3NaO7
+ [MNa]+ 498.2211, found
498.2225.
(2S)-Methyl-2-(4-acetyl-3-((S)-1-((tert-butoxycarbonyl)(methyl)-
amino)-2-phenylethyl )-2,6-dioxopiperazin-1-yl )-3-phenyl-
propanoate, 20. Prepared according to the general procedure
above from 16; FC: ethyl acetate–n-hexane, 1 : 1.5; yield:
117 mg (71%), as an inseparable mixture of diastereoisomers
(d.e. 80%, NMR analysis); thick oil; Rf 0.39 (1.5 : 1 n-hexane–
EtOAc); 1H NMR (400 MHz, CD3CN, rotameric mixture of two
diastereoisomers) δ 7.36–7.07 (m, 10H), 5.56–5.40 (m, 1H),
5.14 (d, J = 9.3 Hz, 0.9H), 5.03 (d, J = 10.5 Hz, 0.1H), 4.95–4.80
(m, 0.9H), 4.65 (d, J = 18.5 Hz, 0.1H), 4.62 (d, J = 18.6 Hz,
0.9H), 4.42 (m, 0.1H), 4.33 (d, J = 18.5 Hz, 1H), 3.71 (s, 0.3H),
3.66 (s, 2.7H), 3.59–3.38 (m, 1H), 3.19–3.03 (m, 1H), 2.92–2.80
(m, 1H), 2.80–2.67 (m, 1H), 2.67 (s, 2.7H), 2.58 (s, 0.3H), 2.10
(s, 2.7H), 2.08 (s, 0.3H), 1.45 (br, s, 9H); 13C NMR (101 MHz,
CD3CN), δ 169.7–168.5 (3C), 167.8 and 167.6 (1C), 154.7 and
154.6 (1C), 138.3–137.8 (1C), 137.2–137.0 (1C), 129.1 (4C),
128.4 and 128.3 (4C), 126.7–126.4 (2C), 79.7–79.4 (1C), 56.2,
54.9–54.6 (1C), 53.8, 52.1 and 52.0 (1C), 46.8 and 46.5 (1C),
34.4–34.2 (2C), 27.9, 27.7 (3C), 21.0 and 20.8 (1C); HRMS (ESI)
calcd for C30H37N3NaO7
+ [MNa]+ 574.2524, found 574.2506.
General procedure for the synthesis of compounds 23–26
Aldehyde (21 or 22) (1.0 mmol, 1 eq.) was dissolved in 1 mL of
dry methanol under nitrogen, 2,2-diethoxyethanamine
(1.0 mmol, 133 mg, 1 eq.) was added and the resulting mixture
was kept under stirring for 2 h at room temperature. Benzoic
acid (1.0 mmol, 122 mg, 1 eq.) and isocyanide (3 or 4)
(1.2 mmol, 1.2 eq.) were sequentially added and the reaction
was stirred for an additional 24 h at room temperature. The
solvent was removed under reduced pressure to aﬀord the
unstable crude Ugi product, which was directly used in the
next step. The crude was dissolved in 4.5 mL of 50% trifluoro-
acetic acid in dichloromethane, and the resulting solution was
kept under stirring for 24 h. The solvent was removed under
reduced pressure to give a residue which was dissolved in
EtOAc (10 mL) and washed with satd aq. NaHCO3 (2 × 10 mL).
The organic layer was dried over Na2SO4 and concentrated
in vacuo to aﬀord the crude product, which was purified by
flash chromatography (FC) as indicated below.
(S)-Methyl 2-((R)-4-benzoyl-3-((S)-1-(((benzyloxy)carbonyl)-
(methyl)amino)ethyl)-2-oxo-3,4-dihydropyrazin-1(2H)-yl)pro-
panoate, 23a and (S)-methyl 2-((S)-4-benzoyl-3-((S)-1-(((benzyl-
oxy)carbonyl)(methyl)amino)ethyl)-2-oxo-3,4-dihydropyrazin-1
(2H)-yl)propanoate, 23b. Prepared according to the above
general procedure from aldehyde 21 and isocyanide 3; FC:
ethyl acetate–n-hexane, 7 : 3; yield: 23a (24 mg, 5%), 23b
(311 mg, 65%). 23a: thick oil; Rf 0.30 (7 : 3 n-hexane–EtOAc);
[α]30D −22.4 (c 0.5, CHCl3); 1H NMR (300 MHz, CDCl3) δ
7.60–7.20 (m, 10H), 6.04 (br, d, J = 5.9 Hz, 1H), 5.68 (d, J = 5.9
Hz, 1H), 5.28 (br, d, J = 9.2 Hz, 1H), 5.20–4.61 (m, 4H), 3.74 (s,
3H), 2.92 (s, 3H), 1.52 (d, J = 7.0 Hz, 3H), 1.24 (br, m, 3H); 13C
NMR (75 MHz, CDCl3) δ 170.9, 168.1, 162.9, 155.0, 136.7,
132.3, 130.8, 128.5–127.7 (9C), 112.3, 110.6, 67.2, 56.8, 52.6,
52.0, 48.0, 29.7, 15.2, 14.9; HRMS (ESI) calcd for
C26H29N3NaO6
+ [MNa]+ 502.1949, found 502.1953. 23b: foam;
Rf 0.37 (7 : 3 n-hexane–EtOAc); [α]
20
D +27.6 (c 1.0, CHCl3);
1H
NMR (400 MHz, CDCl3, 1 : 1 mixture of rotamers) δ 7.61–7.40
(m, 5H), 7.39–7.27 (m, 5H), 5.96 (br, m, 0.5H), 5.88 (br, d, J =
5.4 Hz, 0.5H), 5.73 (m, 1H), 5.42–5.29 (m, 1H), 5.20–4.95 (m,
3H), 4.93–4.74 (m, 1H), 3.77 (s, 1.5H), 3.74 (s, 1.5H), 3.00 (s,
1.5H), 2.94 (s, 1.5H), 1.50 (d, J = 7.1 Hz, 1.5H), 1.38 (d, J = 7.3
Hz, 1.5H), 1.35–1.24 (m, 3H); 13C NMR (100 MHz, CDCl3) δ
171.6 and 170.9 (1C), 168.7 and 168.6 (1C), 163.1 and 162.9
(1C), 156.6, 137.0, 134.0 and 133.9 (1C), 131.1 and 131.0 (1C),
128.6–127.4 (9C), 111.9 and 111.0 (1C), 111.4 and 110.3 (1C),
67.3 and 67.0 (1C), 57.9 and 57.1 (1C), 52.5, 52.0 and 50.3 (1C),
50.1 and 49.0 (1C), 29.1 and 28.8 (1C), 15.9–14.4 (2C); HRMS
(ESI) calcd for C26H29N3NaO6
+ [MNa]+ 502.1949, found
502.1961.
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(S)-Methyl 2-((R)-4-benzoyl-3-((S)-1-(((benzyloxy)carbonyl)-
(methyl)amino)ethyl)-2-oxo-3,4-dihydropyrazin-1(2H)-yl)-3-phe-
nylpropanoate, 24a and (S)-methyl 2-((S)-4-benzoyl-3-((S)-1-
(((benzyloxy)carbonyl)(methyl)amino)ethyl)-2-oxo-3,4-dihydro-
pyrazin-1(2H)-yl)-3-phenylpropanoate, 24b. Prepared accord-
ing to the above general procedure from aldehyde 21 and
isocyanide 4; FC: ethyl acetate–n-hexane, 3 : 7; yield: 24a
(16 mg, 3%), 24b (223 mg, 40%). 24a: colorless oil; Rf 0.23
(7 : 3 n-hexane–EtOAc); [α]20D −13.6 (c 0.9, CHCl3); 1H NMR
(300 MHz, CDCl3) δ 7.61–7.08 (m, 15H), 5.93 (br, d, J = 5.9 Hz,
0.7H), 5.75 (br, d, J = 5.9 Hz, 0.3H), 5.66 (d, J = 5.9 Hz, 0.7H),
5.60 (d, J = 5.9 Hz, 0.3H), 5.36–4.97 (m, 4H), 4.72 (m, 0.3H),
4.33 (dq, J = 10.7 and 6.8 Hz, 0.7H), 3.82 (s, 2.1H), 3.80 (s,
0.9H), 3.48 (dd, J = 14.7 and 4.9 Hz, 0.7H), 3.43 (dd, J = 14.7
and 4.9 Hz, 0.3H), 3.17 (dd, J = 14.7 and 12.7 Hz, 0.7H), 3.04
(dd, J = 13.8 and 11.7 Hz, 0.3H), 2.92 (s, 0.9H), 2.85 (s, 2.1H),
0.73 (d, J = 6.8 Hz, 2.1H), 0.64 (d, J = 6.8 Hz, 0.9H); 13C NMR
(75 MHz, CDCl3) δ 170.0, 168.7, 163.7 and 163.2 (1C), 155.9,
136.0, 135.7, 133.8, 130.8, 129.1–127.2 (14C), 111.8 and 111.3
(1C), 111.0 and 110.0 (1C), 67.4 and 67.0 (1C), 57.7, 56.7, 55.0,
52.7, 34.8, 28.5, 14.6 and 14.3 (1C); HRMS (ESI) calcd for
C32H33N3NaO6
+ [MNa]+ 578.2262, found 578.2250. 24b: oil; Rf
0.27 (7 : 3 n-hexane–EtOAc); [α]20D +34.5 (c 1.0, CHCl3);
1H NMR
(400 MHz, CDCl3) δ 7.56–7.18 (m, 15H), 5.90 (d, J = 5.9 Hz,
0.7H), 5.78 (br, d, J = 5.7 Hz, 1H), 5.72 (dd, J = 11.3 and 5.4 Hz,
0.3H), 5.59 (m, 1H), 5.38 (br, d, J = 9.3 Hz, 0.7H), 5.23–5.01 (m,
2.3H), 4.83 (br, m, 1H), 3.73 (s, 2.1H), 3.70 (s, 0.9H), 3.45 (dd,
J = 14.4 and 5.4 Hz, 0.3H), 3.40 (dd, J = 14.4 and 5.7 Hz, 0.7H),
3.02 (dd, J = 14.4 and 10.8 Hz, 1H), 2.90 (s, 2.1H), 2.86 (s,
0.9H), 1.25 (m, 3H); 13C NMR (100 MHz, CDCl3) δ 170.2, 168.6,
163.7 and 163.3 (1C), 156.6 and 156.0 (1C), 137.0 and 136.6
(1C), 135.7, 133.9, 131.0, 129.3–126.9 (14C), 112.7 and 111.6
(1C), 111.4 and 110.4 (1C), 67.0 and 66.9 (1C), 57.8 and 57.4
(1C), 54.6 and 54.4 (1C), 52.5, 49.9 and 49.7 (1C), 36.7, 28.9,
15.2 and 15.1 (1C); HRMS (ESI) calcd for C32H33N3NaO6
+
[MNa]+ 578.2262, found 578.2248.
(S)-Methyl 2-((R)-4-benzoyl-3-((S)-1-(((benzyloxy)carbonyl)-
(methyl)amino)-2-phenylethyl)-2-oxo-3,4dihydropyrazin-1(2H)-
yl)propanoate, 25a and (S)-methyl 2-((S)-4-benzoyl-3-((S)-1-
(((benzyloxy)carbonyl)(methyl)amino)-2-phenylethyl)-2-oxo-3,4-
dihydropyrazin-1(2H)-yl)propanoate, 25b. Prepared according
to the above general procedure from aldehyde 22 and isocya-
nide 3; FC: ethyl acetate–n-hexane, 1 : 1.5; yield: 25a (27 mg,
5%), 25b (372 mg, 67%). 25a: colorless oil; Rf 0.19 (1.5 : 1
n-hexane–EtOAc); [α]20D −5.9 (c 0.5, CHCl3); 1H NMR (300 MHz,
CDCl3) δ 7.74–6.96 (m, 15 H), 6.47 (d, J = 6.8 Hz, 0.5H), 6.32 (d,
J = 6.8 Hz, 0.5H), 6.09–6.01 (m, 0.5H), 5.93–5.84 (m, 0.5H),
5.36–4.83 (m, 4.5H), 4.49 (m, 0.5H), 3.75 (s, 1.5H), 3.70 (s,
1.5H), 3.18–2.69 (m, 5H), 1.32 (d, J = 7.8 Hz, 3H); 13C NMR
(75 MHz, CDCl3) δ 173.0, 167.4, 162.8, 160.2 and 159.6 (1C),
137.2, 136.2, 133.0, 131.8, 129.4–127.1 (14C), 112.1–112.3 (2C),
68.1 and 66.8 (1C), 53.4, 52.8, 52.5, 48.3, 37.9 and 37.6 (1C),
29.1, 18.2; HRMS (ESI) calcd for C32H33N3NaO6
+ [MNa]+
578.2262, found 578.2270. 25b: pale yellow oil; Rf 0.35 (1.5 : 1
n-hexane–EtOAc); [α]20D −72.1 (c 0.5, CHCl3); 1H NMR
(400 MHz, CDCl3) δ 7.61–7.11 (m, 15H), 5.91 (br, d, J = 5.6 Hz,
0.6H), 5.82–5.74 (m, 1H), 5.70 (d, J = 5.8 Hz, 0.4H), 5.51 (d, J =
9.8 Hz, 0.6H), 5.42 (d, J = 7.6 Hz, 0.4H), 5.13 (m, 1H), 5.06–4.90
(m, 2.6H), 4.81 (d, J = 13.0 Hz, 0.4H), 3.77 (s, 1.8H), 3.74 (s,
1.2H), 3.17–2.92 (m, 1.6H), 2.97 (s, 1.8H), 2.87 (s, 1.2H), 2.78
(dd, J = 13.9 and 8.1 Hz, 0.4H), 1.49 (d, J = 7.2 Hz, 1.2H), J = 7.5
Hz, 1.8H); 13C NMR (100 MHz, CDCl3) δ 170.7, 169.3, 163.3,
157.5 and 157.0 (1C), 138.0 and 137.8 (1C), 137.3 and 137.1
(1C), 134.5 and 134.3 (1C), 132.0 and 131.7 (1C), 129.4–127.1
(14C), 113.4–111.1 (2C), 67.9 and 67.5 (1C), 59.3 and 58.4 (1C),
57.4 and 54.1 (1C), 53.2 and 52.9 (1C), 51.3 and 51.0 (1C), 36.2
and 35.6 (1C), 29.9 and 29.8 (1C), 15.5 and 15.0 (1C); HRMS
(ESI) calcd for C32H33N3NaO6
+ [MNa]+ 578.2262, found
578.2268.
(S)-Methyl 2-((R)-4-benzoyl-3-((S)-1-(((benzyloxy)carbonyl)-
(methyl)amino)-2-phenylethyl)-2-oxo-3,4-dihydropyrazin-1(2H)-
yl)-3-phenylpropanoate, 26a and (S)-methyl 2-((S)-4-benzoyl-3-
((S)-1-(((benzyloxy)carbonyl)(methyl)amino)-2-phenylethyl)-2-
oxo-3,4-dihydropyrazin-1(2H)-yl)-3-phenylpropanoate, 26b.
Prepared according to the above general procedure from alde-
hyde 22 and isocyanide 4; FC: ethyl acetate–n-hexane, 3 : 7;
yield: 26a (56 mg, 9%), 26b (284 mg, 45%). 26a: colorless oil;
Rf 0.22 (7 : 3 n-hexane–EtOAc); [α]
30
D −11.1 (c 0.5, CHCl3); 1H
NMR (300 MHz, CDCl3, complex mixture of conformers) δ
7.68–6.81 (m, 20H), 6.38 (d, J = 5.8 Hz, 0.1H), 5.94–5.80 (m,
0.7H), 5.79–5.72 (m. 0.2H), 5.72–5.54 (m, 1H), 5.51–5.37 (m,
0.5H), 5.31–4.65 (m, 4.5H), 3.74 (s, 0.3H), 3.70 (s, 2H), 3.67 (s,
0.7H), 3.49–3.18 (m, 1H), 3.16–2.87 (m, 3H), 2.83 (s, 0.7H),
2.80 (s, 2H), 2.72 (s, 0.3H); 13C NMR (75 MHz, CDCl3) δ
170.2–169.6 (1C), 168.9–168.4 (1C), 163.6 and 163.1 (1C), 157.0
and 156.8 (1C), 137.3–135.7 (4C), 131.8–130.9 (1C), 129.3–126.5
(19C), 112.5–106.7 (2C), 68.1–66.8 (1C), 58.0 and 57.7 (1C),
57.3–57.0 (1C), 55.8–55.3 (1C), 54.1–52.2 (2C), 38.0–37.6 (1C),
35.3–34.7 (1C), 29.4 and 29.0 (1C); HRMS (ESI) calcd for
C38H37N3NaO6
+ [MNa]+ 654.2575, found 654.2561. 26b: foam;
Rf 0.30 (7 : 3 n-hexane–EtOAc); [α]
20
D −139.8 (c 1.0, CHCl3); 1H
NMR (400 MHz, CD3CN, a mixture of two conformers 1.5 : 1) δ
7.64–7.01 (m, 20H), 6.01 (m, 0.8H), 5.96 (d, J = 5.9 Hz, 0.6H),
5.79 (d, J = 5.4 Hz, 0.6H), 5.63 (dd, J = 11.1 and 5.4 Hz, 0.4H),
5.53 (dd, J = 10.8 and 5.4 Hz, 0.6H), 5.15–4.87 (m, 3.6H), 4.69
(d, J = 12.9 Hz, 0.4H), 3.71 (s, 3H), 3.43 (dd, J = 14.7 and 5.4
Hz, 0.4H), 3.37 (dd, J = 14.7 and 5.4 Hz, 0.6H), 3.08 (dd, J =
14.7 and 11.1 Hz, 0.4H), 3.07 (dd, J = 14.7 and 0.81 Hz, 0.6H),
3.04–2.87 (m, 2H), 2.83 (s, 3H); 13C NMR (100 MHz, CD3CN) δ
170.1 and 169.9 (1C), 168.5 and 168.4 (1C), 163.6 and 163.3
(1C), 156.6 and 155.8 (1C), 138.0 and 137.4 (1C), 136.5 and
136.4 (2C), 134.2 and 133.8 (1C), 131.1 and 130.9 (1C),
129.1–126.4 (19C), 112.0–111.5 (2C), 66.5 and 66.3 (1C), 57.2
and 57.1 (1C), 56.0, 55.1–54.8 (2C), 52.2 and 52.1 (1C), 36.1
and 35.9 (1C), 34.9 and 34.6 (1C), 29.0 and 28.8 (1C); HRMS
(ESI) calcd for C38H37N3NaO6
+ [MNa]+ 654.2575, found
654.2558.
Computational studies
Conformational analysis of compound 9. MMFF and DFT
calculations were run with Spartan’10 (Wavefunction, Inc.,
Irvine, CA, 2010), with standard parameters and convergence
Organic & Biomolecular Chemistry Paper
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criteria. TDDFT calculations were run with Gaussian’09,27 with
default grids and convergence criteria. Conformational
searches were run with the Monte Carlo algorithm
implemented in Spartan’10 using Merck molecular force field
(MMFF) in vacuo. All structures thus obtained were optimized
with the DFT method using the B3LYP functional and the
6-31G(d) basis set in vacuo. TDDFT calculations were run using
the CAM-B3LYP functional and the SVP basis set, including 36
excited states (roots). On some representative structures, we
verified the consistency with the results obtained with the
larger TZVP basis set. CD spectra were generated using the
program SpecDis29 by applying a Gaussian band shape with
0.3 eV exponential half-width, from dipole-length rotational
strengths. The diﬀerence with dipole-velocity values was found
to be minimal for all relevant transitions.
Computational studies on models a, b and c. The starting
geometries of compounds a, b and c (Fig. 4), created by Gauss-
View,27 were energy minimized by the conjugate gradient
algorithm implemented in Gaussian09.27 Thus, the optimized
geometries were subjected to heating, equilibration, and mole-
cular dynamics simulation by the sander module of AMBER
12.25 GAFF force fields were used for the parameterization of
the molecules, modeled as neutral compounds in an implicit
GB solvent model and a dielectric continuum of 80 (simulating
water).26 With a time step of 2 fs, each peptidomimetic was
heated to 300 K, 700 K and then to 1000 K over 20 ps. After an
equilibration phase of 2 ns, each model were frozen to 700 K
and then to 300 K over 20 ps. The production run of the MD
simulations was performed for a total time of 20 ns with trajec-
tories saved every 10 ps. The resulting structures in the trajec-
tories were visually analyzed by VMD.30 In this stage, the
fluctuations of the diverse torsion angles were analyzed and
the diﬀerent families of conformers were identified. They were
then minimized using Gaussian09 at the DFT/B3LYP/6-31g(d)
level of theory and the lowest energy conformation, and the
Boltzmann equation was applied to calculate the conformer
percentage distribution (Fig. 4). Cβ–Cβ distances were
measured using GaussView.
Biological evaluation
Cytotoxicities of compounds 9–12, 17–20 and 23–26. Cyto-
toxic activities were investigated using the NCI-SRB method on
epithelial-like (Huh7) and PTEN deficient mesenchymal like
Mahlavu cells.31 Cytotoxic eﬀects of the compounds were
observed after 72 hours (see ESI†). Human liver cancer cells
(Huh7 and Mahlavu) were grown in Dulbecco’s modified Eagle
medium (DMEM), with 10% fetal bovine serum, 1% non-
essential amino acids and 1% penicillin/streptomycin (GIBCO,
Invitrogen) at 37 °C under 5% CO2.
NCI-60 Sulforhodamine B (SRB) assay. Huh7 and Mahlavu
liver cancer cells were grown in 96-well plates (2000 cells per
well in 150 µl). After 24 h, one plate for each cell line was fixed
with 100 μl 10% ice-cold trichloroacetic acid (TCA). This plate
represents the behavior of the cells just prior to drug treatment
and is accepted as the time-zero plate (Tz). Then they were
treated with serial dilution concentrations of the compounds
(40, 20, 10, 5, and 2.5 µM) dissolved in dimethyl sulfoxide
(DMSO). The corresponding DMSO vehicles were also applied
to Huh7 and Mahlavu cells as negative controls. DMSO con-
centrations were always below 0.01%. After 72 h, cells were
washed with 1×PBS (CaCl2-, MgCl2-free) (Gibco, Invitrogen),
and then fixed with cold 10% (v/v) trichloroacetic acid
(MERCK). Microplates were left for 1 h at 4 °C, then washed
with water and left to dry. The plates were then stained with
100 μl of 0.4% sulphorhodamine B (SRB) (Sigma Aldrich) in a
1% acetic acid solution for 10 min. The unbound SRB was
washed with 1% acetic acid. SRB was then solubilized in 200 μl
of 10 mM Tris-base solution. The absorbance was read at
515 nm. The experiment was performed in duplicate and the
absorbance values were normalized to DMSO controls and Tz
values. Standard deviations were less than 10%.
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